Advanced Non-hematologic Malignancies Clinical Trial
Official title:
A Multicenter, Open-label, Dose-escalation, Phase I Study of TAK-733, an Oral MEK Inhibitor, in Adult Patients With Advanced Nonhematologic Malignancies
The purpose of this study is to evaluate the safety, pharmacokinetics, pharmacodynamics and maximum tolerated dose of TAK-733 in patients with advanced, nonhematologic tumors. The expansion stage of the study will evaluate evidence of antitumor activity of TAK-733 in patients with advanced metastatic melanoma.
n/a
Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Terminated |
NCT00915278 -
A Safety Study Of A Monoclonal Antibody Against A5B1 Integrin In Solid Tumors
|
Phase 1 | |
| Completed |
NCT01653158 -
CP-751,871 In Combination With Docetaxel In Advance Non-hematologic Malignancies
|
Phase 1 | |
| Completed |
NCT00830869 -
A Phase 1 Study of IXAZOMIB in Adult Patients With Advanced Nonhematologic Malignancies
|
Phase 1 |